Radboud University Medical Center
To prospectively assess the incidence of peritoneal carcinomatosis for women with isolated STIC (serous tubal intraepithelial carcinoma). Moreover, to identify histopathological characteristics of STIC which are reproducible and associated to the risk of peritoneal carcinomatosis and to report the findings of additional diagnostics.
BRCA Mutation
Serous Tubal Intraepithelial Carcinoma
Ovarian Carcinoma
Peritoneal Carcinoma
No intervention, only registration
Women with a BRCA pathogenic variant (PV) undergo a risk-reducing salpingo-oophorectomy (RRSO) to reduce their ovarian cancer risk of 17-44%. A residual risk for peritoneal cancer (PC) persists, with most patients having extensive tumour spread throughout the abdomen. Despite surgery and chemotherapy, the five-year survival rate of PC is only 14-30%. Recently it became apparent that PC is frequently preceded by a preinvasive serous tubal intraepithelial cancer (STIC) at RRSO. The entity STIC is often found conjointly with ovarian cancer, but can also be present as an isolated condition, mostly in high risk women. If this STIC is found at RRSO, the risk for PC was found to be 27.5% (95% CI, 15.6-43.9) after ten years whilst this risk was <1% without STIC. The pathophysiological mechanism of this association is not yet known and it is unknown which women with STIC are most at risk. Moreover, the additional value of diagnostics and management is unknown as data is lacking. Objective: To prospectively assess the PC incidence for women with isolated STIC, to identify histopathological characteristics of STIC which are reproducible and associated to the risk of PC, and to report the findings of additional diagnostics.
Study Type : | Observational |
Estimated Enrollment : | 600 participants |
Official Title : | International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis |
Actual Study Start Date : | June 2024 |
Estimated Primary Completion Date : | June 2034 |
Estimated Study Completion Date : | June 2034 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 100 Years |
Sexes Eligible for Study: | Female |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.